Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
Masashi Ishikawa,Makoto Sonobe,Ei Nakayama,Masashi Kobayashi,Ryutaro Kikuchi,Jiro Kitamura,Naoto Imamura,Hiroshi Date +7 more
TLDR
In lung adenocarcinoma, Axl and Gas6 expression levels were associated with tumor advancement and patient survival, thus rendering them as reliable biomarkers and potential targets for treatment of lungAdenocARCinoma.Abstract:
Background
Downstream activation through receptor tyrosine kinases (RTKs) plays important roles in carcinogenesis. In this study, we assessed the clinical involvement of Axl, an RTK, and its ligand, Gas6, in surgically treated lung adenocarcinoma.read more
Citations
More filters
Journal ArticleDOI
Giving AXL the axe: targeting AXL in human malignancy.
TL;DR: Evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.
Journal ArticleDOI
AXL kinase as a novel target for cancer therapy
TL;DR: The data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis are highlighted, and future perspectives in this emerging field are highlighted.
Journal ArticleDOI
Axl as a mediator of cellular growth and survival
TL;DR: The oncogenic nature of Axl is demonstrated through its activation of signaling pathways involved in proliferation, migration, inhibition of apoptosis, and therapeutic resistance, which must be analyzed in a cell type-specific context.
Journal ArticleDOI
The Receptor Tyrosine Kinase AXL in Cancer Progression
Erinn B. Rankin,Amato J. Giaccia +1 more
TL;DR: The literature that has illuminated the cellular and molecular mechanisms by which AXL signaling promotes tumor progression are reviewed and the therapeutic potential of AXL inhibition for cancer therapy is discussed.
Journal ArticleDOI
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
Marie Schoumacher,Mike Burbridge +1 more
TL;DR: The optimal design of treatment strategies to maximize the clinical benefit of these AXL and MER targeting agents are discussed in relation to the different cancer types and the types of resistance encountered.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
BookDOI
TNM classification of malignant tumours
TL;DR: Head and Neck Tumours.- Lip and Oral Cavity.- Pharynx.- Larynx.' Maxillary Sinus.- Salivary Glands.- Thyroid Gland.- Digestive System Tumour .
Book
Pathology and genetics of tumours of the lung , pleura, thymus and heart
TL;DR: This book will not become a unity of the way for you to get amazing benefits at all, but, it will serve something that will let you get the best time and moment to spend for reading the book.
Related Papers (5)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang,Zhenfeng Zhang,Jae Cheol Lee,Luping Lin,Victor Olivas,Valerie Au,Thomas LaFramboise,Mohamed Abdel-Rahman,Xiaoqi Wang,Alan D. Levine,Jin Kyung Rho,Yun Jung Choi,Chang-Min Choi,Sang We Kim,Se Jin Jang,Young Soo Park,Woo Sung Kim,Dae Ho Lee,Jung Shin Lee,Vincent A. Miller,Maria E. Arcila,Marc Ladanyi,Philicia Moonsamy,Charles L. Sawyers,Titus J. Boggon,Patrick C. Ma,Carlota Costa,Miquel Taron,Rafael Rosell,Balazs Halmos,Trever G. Bivona,Trever G. Bivona +31 more
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai T. Tran,Robert J. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy L. Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun Ki Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach +33 more